COMPASS Pathways (NasdaqGS:CMPS) is back in focus as investors watch the final stages of its planned FDA application for COMP360, a synthetic psilocybin treatment for people with treatment-resistant depression.

Over the past year, COMPASS Pathways has seen strong momentum, with a year to date share price return of 127.18% and a 1 year total shareholder return of 212.61%. The recent 32.15% 30 day share price return suggests that enthusiasm around the FDA submission is building further.

Scan beyond COMPASS Pathways and compare this move in mental health biotech to a hand picked 18 high quality undiscovered gems that could be next in line for attention.

After a move like this, COMPASS Pathways now asks investors a simple question: Does the potential reward for COMP360 and its late stage FDA push still justify the risks at today’s price, once you run the numbers?

Most Popular Narrative: 39.2% Undervalued

Based on the most widely followed narrative, COMPASS Pathways is priced at $14.88 against an estimated fair value of $24.47, which puts a spotlight on what is assumed for COMP360.

Completion of enrollment in the COMP006 Phase III trial and the plan to use 9 week data from Part A together with 26 week COMP005 data to support a rolling NDA process could shorten the path to potential approval, which would bring revenue forward and may support earlier earnings visibility.

Read the complete narrative. Read the complete narrative.

Want to understand why this narrative still finds upside at this price? It leans on ambitious revenue ramps, rising margins and a rich future earnings multiple. Curious which assumptions really carry the valuation load?

Result: Fair Value of $24.47 (UNDERVALUED)

However, COMPASS Pathways still faces clinical and funding risks, including potential Phase III setbacks and the possibility of further dilution if cash needs exceed current resources.

Next Steps

If this mix of optimism and concern around COMPASS Pathways feels familiar, treat it as a prompt to move quickly and test the numbers yourself. Weigh both sides of the story in detail by checking the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond COMPASS Pathways?

If COMPASS Pathways has your attention, do not stop here. Broaden your watchlist now so you are not reacting late when the next story breaks.

• Target future potential by reviewing 49 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their business strength.
• Prioritise stability and capital protection by checking a 74 resilient stocks with low risk scores that focuses on companies with more resilient risk profiles.
• Strengthen your foundation with a list of solid balance sheet and fundamentals (51 results) so you are backing businesses with healthier debt and liquidity positions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.